Search Results - nanobody

8 Results Sort By:
Dynamic Extension of the Eyebox for Maxwellian View AR Waveguides (Case No. 2024-163)
Summary: Researchers in the Department of Electrical & Computer Engineering have developed a new metasurface material that improves the size and resolution of augmented reality overlays. Background: Augmented reality (AR) waveguide displays have revolutionized the way users can interact with virtual content overlaid in the real world. High...
Published: 11/4/2024   |   Inventor(s): Chee Wei Wong, Hyunpil Boo
Keywords(s): artificial electromagnetic materials, artificial-intelligent materials, Augmented Reality, augmented reality (AR), bacterial nanocellulose, Carbon Nanotube, Composite Materials, Construction Materials, Extended reality, Functional Materials, intercalated materials, liquid crystal nanofibers, Materials, Medical Devices and Materials, meta materials, metal nanocomposites, metasurfaces, microarchitectured materials, Microfluidics Nanosphere, Mixed Reality, nanobody, nanocomposite scintillators, Nanocomposites, Nanocrystal, nanocrystalline metals, nanodispersion, Nanoelectronics, Nanoemulsion droplet, Nanofiber, nanograined metals, Nanomaterials, Nanoparticle, Nanoparticles, nanophotonic, nanophotonic structures, nanophotonics, Nanosensor, Nanostructure, nanostructured materials, Nanotechnology, Optoelectronic materials, photonic materials, Raw materials supplier, Toxicity Of Nanomaterials, Ultrahard materials/abrasives, Virtual Reality, Virtual Reality Braille Haptic Technology Joule Heating, Virtual Reality Occupational Therapy Exercise Machine, Water Purification, Nanofiltration, Ultrafiltration, zzsemiconducting materials
Category(s): Software & Algorithms, Software & Algorithms > Ar/Vr, Materials, Materials > Composite Materials, Materials > Functional Materials, Materials > Nanotechnology
Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....
Published: 6/28/2024   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer, CAR-T cell platform, CAR-T cell therapy, cell engineering, Immunotherapy, Mesothelin, nanobody, Nanoparticle
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
: Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes
Abstract: Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer...
Published: 12/23/2024   |   Inventor(s): Mitchell Ho, Zhijian Duan, Christian Hinrichs
Keywords(s): adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
Abstract: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-1
Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors
Abstract: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.  PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1...
Published: 4/8/2024   |   Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day
Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics